Equities research analysts forecast that vTv Therapeutics Inc. (NASDAQ:VTVT – Get Rating) will post ($0.10) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for vTv Therapeutics’ earnings. vTv Therapeutics posted earnings per share of ($0.01) in the same quarter last year, which suggests a negative year over year growth rate of 900%. The company is expected to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that vTv Therapeutics will report full-year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.47) to $0.02. For the next year, analysts expect that the firm will report earnings of ($0.45) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT – Get Rating) last issued its quarterly earnings results on Tuesday, March 29th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $1.00 million.
Several large investors have recently made changes to their positions in VTVT. Samsara BioCapital LLC purchased a new stake in shares of vTv Therapeutics during the 4th quarter worth approximately $1,627,000. Cim Investment Management Inc. lifted its stake in vTv Therapeutics by 100.0% in the 4th quarter. Cim Investment Management Inc. now owns 354,746 shares of the biotechnology company’s stock valued at $447,000 after buying an additional 177,373 shares in the last quarter. Geode Capital Management LLC lifted its stake in vTv Therapeutics by 77.2% in the 3rd quarter. Geode Capital Management LLC now owns 347,635 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 151,435 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in vTv Therapeutics in the 3rd quarter valued at approximately $177,000. Finally, Rafferty Asset Management LLC purchased a new stake in vTv Therapeutics in the 3rd quarter valued at approximately $83,000. 7.35% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ VTVT traded down $0.01 on Wednesday, hitting $0.50. 121,485 shares of the company’s stock were exchanged, compared to its average volume of 252,612. The firm’s 50-day moving average price is $0.63 and its two-hundred day moving average price is $0.85. vTv Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $2.88. The firm has a market cap of $45.02 million, a price-to-earnings ratio of -2.08 and a beta of -1.43.
About vTv Therapeutics (Get Rating)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.
- Get a free copy of the StockNews.com research report on vTv Therapeutics (VTVT)
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- It’s Time to Buy into Planet Fitness Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.